{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:12:28Z","timestamp":1776445948132,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.molimm.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T02:09:37Z","timestamp":1710986977000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells"],"prefix":"10.1016","volume":"169","author":[{"given":"Yuxi","family":"Dan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liaoqiong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2024.03.003_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108301","article-title":"Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises","volume":"240","author":"Anestopoulos","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.molimm.2024.03.003_bib2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular vesicles in cancer: cell-to-cell mediators of metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.molimm.2024.03.003_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molimm.2024.03.003_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00438","article-title":"Immature, semi-mature, and fully mature dendritic cells: toward a dc-cancer cells interface that augments anticancer immunity","volume":"4","author":"Dudek","year":"2013","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/thno.29431","article-title":"Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy","volume":"9","author":"Gao","year":"2019","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.molimm.2024.03.003_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092280","article-title":"Extracellular vesicles and their current role in cancer immunotherapy","volume":"13","author":"Giacobino","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.molimm.2024.03.003_bib7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/annonc\/mdy185","article-title":"Advances in the systemic treatment of melanoma brain metastases","volume":"29","author":"Glitza Oliva","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molimm.2024.03.003_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.semcancer.2023.02.002","article-title":"Extracellular vesicles as next generation immunotherapeutics","volume":"90","author":"Greening","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imm.12874","article-title":"Exosomes from heat-stressed tumour cells inhibit tumour growth by converting regulatory T cells to Th17 cells via IL-6","volume":"154","author":"Guo","year":"2018","journal-title":"Immunology"},{"issue":"10-11","key":"10.1016\/j.molimm.2024.03.003_bib10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.addr.2011.05.021","article-title":"Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations","volume":"63","author":"Hamdy","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molimm.2024.03.003_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.molimm.2024.03.003_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.molimm.2024.03.003_bib13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.176.6.1693","article-title":"Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\/macrophage colony-stimulating factor","volume":"176","author":"Inaba","year":"1992","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.molimm.2024.03.003_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1614857","article-title":"Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial","volume":"8","author":"Ji","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.molimm.2024.03.003_bib15","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.2147\/IJN.S313912","article-title":"Tumor-derived extracellular vesicles: their role in immune cells and immunotherapy","volume":"Volume 16","author":"Li","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.molimm.2024.03.003_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119464","article-title":"Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma","volume":"223","author":"Luo","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.molimm.2024.03.003_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01152","article-title":"Immunotherapy based on dendritic cell-targeted\/-derived extracellular vesicles\u2014a novel strategy for enhancement of the anti-tumor immune response","volume":"10","author":"Markov","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.molimm.2024.03.003_bib19","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1007\/s10238-023-01159-1","article-title":"The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study","volume":"23","author":"Mollica","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1779991","article-title":"Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy","volume":"9","author":"Naseri","year":"2020","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.molimm.2024.03.003_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23062904","article-title":"Bladder cancer extracellular vesicles elicit a CD8 T cell-mediated antitumor immunity","volume":"23","author":"Ortiz-Bonilla","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"Supplement_4","key":"10.1016\/j.molimm.2024.03.003_bib22","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.molimm.2024.03.003_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006947","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0","volume":"11","author":"Pavlick","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.molimm.2024.03.003_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"PW","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2024.03.003_bib25","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2019.4745","article-title":"Role of tumor\u2011derived extracellular vesicles in cancer progression and their clinical applications (Review)","author":"Qiao","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"11","key":"10.1016\/j.molimm.2024.03.003_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29184","article-title":"Vaccine escape challenges virus prevention: the example of two vaccine-preventable oncogenic viruses","volume":"95","author":"Qu","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.molimm.2024.03.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101041","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"issue":"2","key":"10.1016\/j.molimm.2024.03.003_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00010-9","article-title":"Nivolumab plus ipilimumab in melanoma brain metastases","volume":"23","author":"Rizzo","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.molimm.2024.03.003_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri3622","article-title":"Regulation of immune responses by extracellular vesicles","volume":"14","author":"Robbins","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.molimm.2024.03.003_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202200027","article-title":"Advanced biomaterials for cell-specific modulation and restore of cancer immunotherapy","volume":"9","author":"Ruan","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.molimm.2024.03.003_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103596","article-title":"The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study","volume":"170","author":"Santoni","year":"2022","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"6","key":"10.1016\/j.molimm.2024.03.003_bib32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.molimm.2024.03.003_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.711565","article-title":"Exosome-Based Vaccines: History, Current State, and Clinical Trials","volume":"12","author":"Santos","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.molimm.2024.03.003_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.molimm.2024.03.003_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061430","article-title":"Systemic therapy of metastatic melanoma: on the road to cure","volume":"13","author":"Steininger","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molimm.2024.03.003_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641307","article-title":"Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer","volume":"12","author":"Sutherland","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2024.03.003_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semcancer.2021.09.004","article-title":"Extracellular vesicles in anti-tumor immunity","volume":"86","author":"Vergani","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.molimm.2024.03.003_bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.molimm.2024.03.003_bib40","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193220","article-title":"Engineering anti-cancer nanovaccine based on antigen cross-presentation","volume":"39","author":"Warrier","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-016-0295-1","article-title":"Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination","volume":"35","author":"Wei","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2024.03.003_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120467","article-title":"Extracellular vesicles: a bright star of nanomedicine","volume":"269","author":"Wu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.molimm.2024.03.003_bib43","doi-asserted-by":"crossref","DOI":"10.3892\/or.2019.7208","article-title":"CD8+ T-cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL\/Fas signaling pathway and, combined with GM\u2011CSF and IL\u201112, enhance the anti\u2011renal cortical adenocarcinoma effect","author":"Xu","year":"2019","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.molimm.2024.03.003_bib44","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7150\/thno.67775","article-title":"Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment","volume":"12","author":"Xu","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01278-3","article-title":"Exosome-based immunotherapy: a promising approach for cancer treatment","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bjc.2017.389","article-title":"Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response","volume":"118","author":"Yang","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.molimm.2024.03.003_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molmed.2017.11.005","article-title":"Metabolic control of CD8+ T cell fate decisions and antitumor immunity","volume":"24","author":"Zhang","year":"2018","journal-title":"Trends Mol. Med."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589024000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589024000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:07:06Z","timestamp":1712729226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589024000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":47,"alternative-id":["S0161589024000567"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2024.03.003","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}